Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290874 · ClinicalTrials.gov registry record · Phase 3
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
A Phase 3 study of Asthma, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,070
- Enrollment target
- 13
- Study locations
NCT01290874 is a Phase 3 study of Asthma that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 1,070 participants, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (31% lower). The trial reports 13 study locations across 10 states.
The verdict
NCT01290874, a Phase 3 study of Asthma, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,070 participants
- Enrollment target
- 13
- Study locations
Study Summary
We are doing this study to learn how genes affect the way that people, specifically Black people, respond to treatment for asthma. Recent studies suggest that people respond differently to some asthma medications (eg Serevent, Foradil). Some people feel better when they use these inhalers, but others may not, and some people get worse. It seems that this difference shows up more often in Blacks than in Whites, which is why we are looking for Black subjects for this study. In all people, this difference seems to depend on their genes or DNA. This study is comparing the use of long acting asthma medications (Serevent, Foradil) to Tiotropium (Spiriva) for the treatment of asthma. Spiriva is used to treat chronic obstructive pulmonary disease (COPD). This study will help to see if this medication is also useful for treating asthma and whether it works better for some people than the current asthma medications.
Conditions Studied
Interventions
- DRUG Tiotropium
- DRUG Salmeterol
- DRUG Formoterol
Study Locations (13)
Georgia
- Urban Family Practice - Marietta
- Albany Area Primary Healthcare, Inc - Newton
New York
- UNYNET - Jefferson Family Medicine - Buffalo
- Montefiore Medical Group - The Bronx
Ohio
- Cleveland Clinic - Cleveland
- Family Medicine Occupational Health Center - Shaker Heights
Florida
- Edward Waters College Medical Center (Mayo) - Jacksonville
Illinois
- Northwestern University - Chicago
Michigan
- Wayne State University - Detroit
Mississippi
- G.A. Carmichael F.H.C. - Canton
Missouri
- Swope Parkway Health Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,070 participants |
| Start Date | 2011-03-30 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290874
The ClinicalTrials.gov registry entry for NCT01290874 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,070 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (31% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Tiotropium is the first listed.
NCT01290874 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Georgia, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT01290874 about?
NCT01290874 is a clinical study titled "Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)". We are doing this study to learn how genes affect the way that people, specifically Black people, respond to treatment for asthma. Recent studies suggest that people respond differently to some asthma medications (eg Serevent, Foradil). Some people feel better when they use these inhalers, but other...
What is the current status of trial NCT01290874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,070 participants. The study started on 2011-03-30. Estimated completion is 2013-07.
What conditions does trial NCT01290874 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01290874?
The interventions under investigation include: Tiotropium (DRUG), Salmeterol (DRUG), Formoterol (DRUG).
Who is sponsoring clinical trial NCT01290874?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01290874 being conducted?
This trial has 13 study locations across Florida, Georgia, Illinois, Michigan, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.